YONGDA SULI
项目

YONGDA SULI

查看更多
YONGDA SULI
项目

YONGDA SULI

查看更多
YONGDA SULI
项目

YONGDA SULI

查看更多
2020

Establishment Time

260 acres

Land occupation area

160 +

Cooperative Customers

Dalian Yongda Suli Pharma Co., Ltd. was established in December 2020, is jointly invested by Suli Pharmaceutical Technology Jiangyin Co., Ltd. and Jiangsu Yongda Pharmaceutical Co., Ltd. Relying on the company's technological advantages, sufficient production capacity and capacity, lean management on production, safety and high standard GMP quatily mangement, Dalian Yongda Suli is pursuing to provide our customers the APIs/intermediates products and CDMO services with stable quality, competitive price and best services.

Promotional Video

YONGDA SULI

Dalian Yongda
Dalian Yongda

Fully Reinforced

Focus on drug R&D and production

Dalian Yongda

R&D

Own a 2000㎡ R&D center in Shanghai

Dalian Yongda

Production Capacity

GMP scale production workshop

Dalian Yongda

Quality Management

Compliant with FDA standards for APIs

ABOUT YONGDA SULI

BLOG

View More +
"Fire Safety, We're on the Move" - 2023 Annual Fire Drill

"Fire Safety, We're on the Move" - 2023 Annual Fire Drill

07

2022-09

Starting in September, these policies will affect doctors nationwide

September, really is the point in time for the big changes in healthcare in 2017, recently I found that many of the heavy policies from the beginning of the year have been implemented this month, and if you didn't notice, you can only be just in the middle of the mountain.

07

2022-09

Pharmaceutical API industry must change the traditional marketing model

With the gradual homogenization of the industry, as well as generic drug giveaway, in increasing the market demand for pharmaceutical APIs expanding at the same time, but also gradually appeared in the supply of pharmaceutical APIs in short supply, the offline retail model has been unable to meet the needs of the market.

07

2022-09

Red and Yellow shares shrink, market value evaporates by $300 million What warning does it give to pharma?

Although the industrial field is far away, but the red and yellow blue in the crisis under the market performance, has been enough to let all the pharmaceutical enterprises to cause alarm: if the status quo of the low cost of violation of the law is not enough to make the pharmaceutical enterprises to enhance the awareness of the compliance of the operation, but due to the crisis of the incident of the performance of the market value as well as the impact of the enterprise's reputation is a fatal thing!

07

2022-09

Offense or Defense? The pharmaceutical industry market is about to change dramatically

In 2018, China's pharmaceutical industry will usher in a decisive year of consistency evaluation. Whether it is the aggressive attacking faction or the defensive faction that chooses to retreat in the big wave, I believe that all of them have already smelled the shake-up that the unstoppable consistency evaluation is going to bring.

视频标题